AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 242 min read$BBIO

Valantine Hannah sold $342K of BBIO

Valantine Hannah sold 5,004 shares of BridgeBio Pharma, Inc. (BBIO) at an average of $68.25 ($68.00–$68.57, $0.34M total) across 2 trades over 2026-06-22 to 2026-06-23 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Valantine Hannah
Published Jun 24, 2026, 10:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 24, 2026, 10:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BBIO
Neutral
medium confidence
Mentioned
$BBIO
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BBIONeutralLow
01

Why it matters

The disclosed event is an open-market sale by a director under a pre-arranged 10b5-1 plan; absent other news, it mainly informs positioning/sentiment rather than fundamentals.

02

Market read

Traders may note the insider selling signal, but the 10b5-1 structure and lack of new business catalysts suggest limited impact.

03

What to watch

The article provides only the sale details; it does not include any offsetting buys, broader insider activity context, or changes in company guidance/operations.

Relevance 3/10Novelty 3/10Timing: after-hours/filing timestamp (2026-06-24) for today’s Form 4 disclosure

Background

The article is a primary-source SEC Form 4 insider transaction for BridgeBio Pharma, Inc. (BBIO).

Company-level read

Ticker impact

$BBIONeutralMedium confidence
Context

BridgeBio Pharma director Valantine Hannah sold $341.5K of BBIO shares via an open-market sale under a 10b5-1 plan (Form 4 filed today).

Expected impact

Likely minimal immediate price impact; any effect would be sentiment-driven and short-lived.

Evidence & confidence

The filing discloses a routine, pre-arranged 10b5-1 sale with modest size relative to typical large-cap float, and no accompanying operational/regulatory catalyst is provided.

Market effects

Sector

No sector read-through; this is a single-company insider transaction with no new clinical/regulatory datapoints.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even 10b5-1 sales can coincide with private information or portfolio rebalancing; traders may still fade/trim risk if multiple insiders sell.

Key entities

  • issuer
    BridgeBio Pharma, Inc.

    Subject of the Form 4 insider transaction; director Valantine Hannah sold shares under a 10b5-1 plan.

  • insider
    Valantine Hannah

    Director who executed two open-market sale trades totaling $341,523.72.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BBIO insider trading history →

Related articles

OCT 7
$BBIOMedAI 9/10

BridgeBio Pharma stock rating reiterated at Buy by Canaccord

Canaccord reiterated a Buy rating and $106 price target for BridgeBio Pharma (BBIO) after positive cardiac data from its LGMD2I/R9 treatment program. The company's stock trades at $66.96, below the target. Analysts maintain a Strong Buy consensus with targets ranging from $80 to $156. BridgeBio estimates a 90% success probability and peak sales of $1.3B by 2034 for the treatment.

investing.com2 min
OCT 6
$BBIOHigh

FDA Accepts BridgeBio's Infigratinib NDA For Priority Review

BridgeBio Pharma (BBIO) announced the FDA accepted its NDA for infigratinib to treat achondroplasia in children, granting Priority Review. The PDUFA target date is February 4, 2027. The NDA is backed by positive Phase 3 study results showing significant improvements in height velocity and body proportionality. BBIO shares rose 1.65% on Friday and are up 3.42% in premarket trading.

rttnews.com2 min
OCT 6
$BBIOHigh

H.C. Wainwright reiterates Buy on BridgeBio stock, cites cardiac data

H.C. Wainwright reiterated a Buy rating and $120 price target on BridgeBio Pharma (BBIO) after positive cardiac data from its muscular dystrophy treatment. The stock is currently at $66.14, with analysts maintaining a Strong Buy consensus and targets ranging from $80 to $157. BridgeBio reported 202% revenue growth and 94% gross margins over the last year, according to InvestingPro.

investing.com1 min
OCT 6
$BBIOMed

BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia

BridgeBio Pharma (BBIO) announced FDA acceptance of its NDA for oral infigratinib to treat children with achondroplasia, with a Priority Review and PDUFA target date of February 4, 2027. The PROPEL 3 trial met primary and key secondary endpoints, showing significant improvements in height velocity and body proportionality. If approved, it would be the first oral therapy for this condition.

globenewswire.com3 min